Aptevo Therapeutics Inc. develops clinical-stage immune-oncology therapeutics for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. News about APVO centers on mipletamig, its CD123 x CD3 program for acute myeloid leukemia, including clinical data, safety observations, orphan drug designation for AML, and combination studies with venetoclax and azacitidine.
Company updates also cover pipeline expansion into bispecific, multispecific and trispecific candidates, solid-tumor work such as ALG.APV-527, conference presentations, financing arrangements, operating results, shareholder voting matters, and governance changes tied to Aptevo’s public-company structure.
Aptevo Therapeutics (NASDAQ: APVO) released its second quarter 2020 financial results, reporting a net loss of $6.8 million or $2.10 per share, a significant decrease from a $13.3 million loss in Q2 2019. The company generated $0.5 million in royalty revenue from Pfizer's RUXIENCE sales, marking its entry into non-dilutive revenue streams. Cash and equivalents stood at $10.2 million, bolstered by a $25 million loan, ensuring operations through Q3 2021. Clinical developments include completion of cohort 6 in the APVO436 trial for AML and high-grade MDS, with promising preclinical data for ALG.APV-527.
Aptevo Therapeutics (NASDAQ: APVO) announced advancements in its clinical trial for APVO436 treating Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS), completing cohort 6 enrollment. The company reported $0.5 million in royalty revenue from Pfizer's RUXIENCE sales and extended its cash runway into Q3 2021 through a $25 million loan. The net loss narrowed to $6.8 million in Q2 2020 from $13.3 million in Q2 2019. Preclinical data for ALG.APV-527 suggests a favorable safety profile, with further development opportunities being explored.